Iovance Biotherapeutics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Unaudited results cover the three months ended March 31, 2024. Iovance is a commercial-stage cell therapy company. The FDA approved Amtagvi (lifileucel) on February 16, 2024, under accelerated approval for certain adults with unresectable or metastatic melanoma after prior treatment. The company also sells Proleukin (aldesleukin), used in the Amtagvi treatment regimen.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparator |
|---|---|---|
| Revenue | $0.7 million | $0 |
| Cost of sales | $7.3 million | $0 |
| Research and development | $79.8 million | $82.7 million |
| Selling, general and administrative | $31.4 million | $28.1 million |
| Operating loss | $117.7 million | $110.9 million |
| Net loss | $113.0 million; $0.42 per share | $107.4 million; $0.50 per share |
| Net cash used in operating activities | $122.3 million | $99.8 million |
Q1 revenue was entirely from Proleukin sales in licensed markets outside the U.S.; no Amtagvi revenue was recognized in the quarter. Cost of sales exceeded revenue, reflecting Proleukin costs, $4.6 million of acquired-technology amortization and $1.9 million of Amtagvi manufacturing overhead and ramp-up costs. The filing does not report a clear gross margin measure.
At March 31, 2024, cash and cash equivalents were $134.2 million, short-term investments $222.0 million and restricted cash $6.4 million, totaling $362.6 million. Working capital was approximately $302.3 million. Total liabilities were $189.8 million, including a $1.0 million long-term note payable and $83.4 million of operating lease liabilities. Stockholders’ equity was $680.0 million.
Changes versus the prior comparable period
- Revenue began following the Proleukin acquisition in 2023; Q1 2024 sales remained modest and Amtagvi sales had not yet begun.
- Net loss increased $5.6 million, or 5%, and operating cash use increased $22.5 million year over year.
- R&D expense fell 4%, primarily as qualified Amtagvi manufacturing costs became capitalizable after approval; SG&A rose 12% as commercialization staffing and launch costs increased.
- The company raised approximately $197.4 million net through a February 2024 public offering of 23.014 million shares, increasing common shares outstanding.
- Iovance paid a $52.6 million Proleukin-acquisition milestone upon Amtagvi approval; the payment was capitalized as an intangible asset. Restricted cash declined from $66.4 million to $6.4 million after cancellation of the related $60 million letter of credit.
Outlook, commentary and risks
Management expects Amtagvi revenue to begin in Q2 2024 and believes available funds can cover planned operating expenses and capital expenditures for at least 12 months from issuance of the financial statements. It cautions that product revenues may not be sufficient to generate positive operating cash flow during that period; significant spending and losses are expected to continue. No numerical revenue or earnings guidance is provided.
Management’s stated launch priority included activating 50 authorized treatment centers within 90 days of the February 24, 2024 PDUFA date. It expects ongoing Amtagvi ramp-up overhead costs in coming quarters, with SG&A expected to rise as commercialization expands. Key risks include manufacturing scale, quality and supply constraints; treatment-center onboarding, reimbursement and market adoption; and clinical, regulatory and financing uncertainty. Amtagvi’s accelerated approval may depend on confirmation of clinical benefit in future trials. The FDA lifted the partial clinical hold on the IOV-LUN-202 NSCLC trial on March 4, 2024, allowing enrollment to resume after a reported fatal serious adverse event.
The company disclosed a proposed settlement in a director compensation derivative action, subject to court approval, including a $0.6 million payment accrued at quarter-end. It said losses in the Solomon litigation could not be estimated, though the company did not believe pending matters would materially affect its financial position, results or cash flows. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether Amtagvi launch, treatment-center activation, patient throughput and reimbursement support meaningful sales and eventual positive cash flow.
- Commercial manufacturing capacity, product release performance, supply reliability and the path to absorbing launch-related overhead.
- Progress and safety outcomes in confirmatory trial TILVANCE-301 and registrational NSCLC study IOV-LUN-202, including any further FDA requirements.
- Cash burn relative to the $362.6 million reported liquidity balance, future financing needs and potential dilution from equity issuance.
- Proleukin acquisition-related payments, deferred consideration and royalty obligations, along with the outcome of the proposed legal settlement.